Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Hypoxia-inducible factor-1 alpha is involved in RIP-induced necroptosis caused by in vitro and in vivo ischemic brain injury
CCR-13-1777
V hold-90mV)
Solubility: DMSO: 5 mg/mL(13
Tofogliflozin hydrate Catalog No.:M10025-2 Hypoxia-inducible factor-1 alpha is involvedTofogliflozin, also known as CSG 452, is a potent and high selective SGLT2 inhibitor under development the treatment of diabetes mellitus. Tofogliflozin improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Tofogliflozin dose dependently suppressed glucose entry into tubular cells. High glucose exposure (30 mM) for 4 and 24 h significantly increased oxidative stress generation in tubular cells, which were
US$ 191.25
US$ 959.75
US$ 1198.83
US$ 1722.71
US$ 141.25
US$ 149.17